Metraipolis › archive › dc_c8bfaa707ea4

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs — Europe PMC PMID:41472235

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41472235
DOI: 10.3390/v17121564
License (as archived): solo-consultazione
Archived: 2026-11-08T04:07:11.190Z
SHA-256 of the archived text: 426b6772602bbaaeb2cda029ea19b56e3eee295d9ddec81e6a2d03f850f872c5
Stable URL of this page: https://metraipolis.com/documento/dc_c8bfaa707ea4

How to cite

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs — Europe PMC PMID:41472235 — Europe PMC (en), https://europepmc.org/article/MED/41472235 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c8bfaa707ea4 (Metraipolis archive dc_c8bfaa707ea4, sha256 426b6772602bbaaeb2cda029ea19b56e3eee295d9ddec81e6a2d03f850f872c5)

BibTeX

@misc{dcc8bfaa707ea4,
  title = {Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs — Europe PMC PMID:41472235},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41472235},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c8bfaa707ea4; sha256 426b6772602bbaaeb2cda029ea19b56e3eee295d9ddec81e6a2d03f850f872c5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41472235. Agents can read the archived copy with the MCP tool read_document.